Welcome to our dedicated page for Astrana Health news (Ticker: ASTH), a resource for investors and traders seeking the latest updates and insights on Astrana Health stock.
Astrana Health Inc. reports developments in physician-centric, technology-enabled healthcare management, including its care delivery infrastructure, proprietary technology platform, and aligned provider networks. The company describes a payer-agnostic, risk-bearing care model designed around coordinated, preventive care and population health management.
Recurring news themes include quarterly and annual financial results, medical cost performance, full-risk contract activity, integration of completed acquisitions, investor-conference presentations, and updates involving governance, capital structure, and operating performance. Company materials also discuss its Care Partners, Care Delivery, and Care Enablement segments.
Astrana Health (NASDAQ: ASTH) announced that company leadership will participate in the J.P. Morgan 2026 Healthcare Conference in San Francisco on Monday, January 12, 2026, including a presentation at 5:15 PM PT. The company said a live webcast and related presentation materials will be posted in the IR Calendar on its investor relations website.
Investors can access the webcast and slides via the company's investor relations page at https://ir.astranahealth.com/news-events/ir-calendar.
Astrana Health (NASDAQ: ASTH) reported third quarter 2025 results and completed the Prospect Health acquisition on July 1, 2025. Q3 total revenue was $956.0M, up 100% YoY, and Adjusted EBITDA was $68.5M, up 52% YoY. Nine‑month total revenue was $2,231.2M (+63% YoY) with Adjusted EBITDA of $153.0M (+13% YoY). Net income attributable to Astrana was $0.4M for Q3 and $16.5M for the nine months. Company reiterated strong clinical and cost trends but updated full‑year guidance timing to reflect certain full‑risk contract delays expected to complete in Q1 2026. Updated 2025 guidance: Revenue $3.10–3.18B, Adjusted EBITDA $200–210M.
Astrana Health (NASDAQ: ASTH) will release financial results for the third quarter ended September 30, 2025 after market close on Thursday, November 6, 2025. The company will host a conference call the same day at 2:30 p.m. PT / 5:30 p.m. ET to discuss results.
An accompanying PDF slide presentation will be posted on the company's IR Calendar page after the earnings release. Live dial-in numbers are 877-858-9810 and +1 201-689-8517; callers are asked to dial in about five minutes early. The call will be webcast and a recording will be available at the provided webcast link shortly after the call.
Astrana Health (NASDAQ: ASTH), a provider-centric, technology-powered healthcare company, has announced its participation in three major upcoming investor conferences in September 2025:
- Wells Fargo Healthcare Conference (September 3-4)
- Morgan Stanley Global Healthcare Conference (September 9) - Including a Fireside Chat from 5:35 PM to 6:10 PM ET
- Baird Healthcare Conference (September 10)
Astrana Health (NASDAQ: ASTH) reported strong Q2 2025 financial results, with total revenue reaching $654.8 million, up 35% year-over-year, and adjusted EBITDA of $48.1 million. The company's Care Partners segment led growth with revenue of $631.4 million, a 36% increase.
Key highlights include the completion of the Prospect Health acquisition for $707.9 million on July 1, 2025, financed through a five-year delayed draw term loan. The company also strengthened its leadership team with several strategic appointments, including Sherry McBride as COO.
Astrana reiterated its full-year 2025 guidance, projecting total revenue between $3.1-3.3 billion and adjusted EBITDA of $215-225 million, which includes the Prospect Health acquisition impact.
Astrana Health (NASDAQ: ASTH), a provider-centric healthcare technology company, has scheduled its Q2 2025 financial results announcement for Thursday, August 7, 2025, after market close.
The company will host a conference call at 2:30 PM PT/5:30 PM ET on the same day to discuss the results. Participants can join via phone (877-858-9810 or +1 201-689-8517) or webcast. A slide presentation will be available on the company's IR website, and a recording will be accessible after the call.
Astrana Health (NASDAQ: ASTH) has completed the acquisition of Prospect Health for $708 million, down from the initially announced $745 million. Prospect Health is a value-based care network with 11,000+ providers serving approximately 600,000 members across multiple states.
The acquisition is expected to contribute $1.2 billion in revenue and $81 million in adjusted EBITDA annually, with anticipated synergies of $12-15 million over the next 12-18 months. Astrana has updated its 2025 guidance to $3.1-3.3 billion in total revenue and $215-225 million in adjusted EBITDA.
Post-acquisition, Astrana will have $700 million in net debt and aims to reduce its net leverage ratio to below 2.5x within 12-18 months.
Astrana Health (NASDAQ: ASTH) reported strong Q1 2025 financial results, with total revenue reaching $620.4 million, up 53% year-over-year. Care Partners revenue increased 57% to $601.0 million. However, net income decreased to $6.7 million from $14.8 million, with diluted EPS of $0.14 compared to $0.31 in Q1 2024.
The company announced key leadership additions, including Georgie Sam as Chief Data & Analytics Officer and Glenn Sobotka as Chief Accounting Officer. Astrana successfully integrated Collaborative Health Systems and received HSR approval for its pending Prospect Health acquisition. For Q2 2025, the company expects revenue between $615-655 million and adjusted EBITDA of $45-50 million. Full-year 2025 guidance projects revenue of $2.5-2.7 billion and adjusted EBITDA of $170-190 million.